The MRC and informed consent Controversy over the Medical Research Council's policies on clinical trials has raised questions about informed consent. Most controversial was a comparison of immediate with deferred orchidectomy in treating certain categories of men with cancer of the prostate. An article in the March issue of the Bulletin of the Institute of Medical Ethics claimed that old men "are being castrated without their informed consent for the benefit of a trial sponsored by the Medical Research Council that is of little, and possibly no, scientific value."' An article in the April Bulletin said that "the Medical Research Council does not believe that the informed consent of a research subject is essential, but is content that research carried out under its auspices should contravene all current national and international guidelines for the conduct of research on humans."2
The MRC has denied these allegations.2 It defended the trial as designed to answer an important clinical question. It denied the charge of indifference to informed consent, citing its own statement on the issue, compliance with which is a condition of all MRC awards for research. The key passage ofits statement on clinical trials says: "In general, the patients participating in them should be told frankly that different procedures are being assessed and their cooperation invited. Occasionally, however, to do so is contraindicated. For example, to awaken patients with a possibly fatal illness to the existence of doubts about effective treatment may not always be in their best interest."
Apart from the disputed question of the scientific value of the trial, the first issue is whether informed consent was obtained. The MRC says that the patient's discussion with the surgeon "follows the surgeon's usual practice subject to the requirements of his local ethical committee," and says that a standard consent form is completed. independent committee." And the guidelines laid down by the Royal College of Physicians, having said that informed consent is "central to the ethical conduct of clinical investigation," allow the possibility of exceptions to be examined by an ethics committee. These may include major procedures "where to obtain 'informed' consent can be impossible or devastating-for example, unconscious patients, acute grave illness, inability to comprehend."
These clauses give the MRC a defence against the charge of breaching all current guidelines. But should the guidelines be so vague? How devastating does the bad news have to be? Is any "acute grave illness" sufficient to remove the patient's rights? And the MRC's own guidelines do not give criteria for exceptions but merely give an example (where raising doubts about effective treatment for a possibly fatal illness may not be in the patient's best interest). How is a researcher, or an ethics committee, to tell in which other cases informed consent is "contraindicated"?
There are two possible arguments for specific exceptions to the requirement. The first is the danger that valuable trials might fail for lack of participants. One viewpoint would give no weight to this argument, on the grounds that the patient has an absolute right to be informed and to participate only voluntarily. Perhaps this is a simplification. Future patients, whose lives may be lost through the trial not being done, are people too, and death is even worse than not being asked for informed consent.
Nevertheless, the dangers of using optimistic predictions about research to justify unacceptable risks to patients are obvious. Clear rules are a protection, and the priority of the interests of the present patient should be maintained. If medical research is going to be devastated by this, we should have a public debate on whether to abandon the Helsinki principle that "concern for the interests of the subject must always prevail over the interests of science and society." Without such debate, the principle stands.
The second argument for exceptions to informed consent appeals to the request's possibly devastating effect. The issue of trials should arise only when there are genuine doubts about the relative effectiveness of treatment. It may sometimes be kinder to keep such doubts from a gravely ill patient, and perhaps a doctor's sensitivity to the particular person is preferable to rigid rules. But violating the informed VOLUME 293 NO 6540 PAGE 157 BRITISH MEDICAL JOURNAL VOLUME 293 19 JULY 1986 consent requirement for a trial is more drastic than merely not spelling out a grim prognosis. The presumption of informed consent should surely be stronger. The exceptions need fuller debate. Exceptions for those unconscious, or unable to understand the request, seem plausible. But can it be right to bypass the requirement of consent in the case of someone capable of understanding the request? With trivial risks it is hard to think many will be disturbed to be asked or will refuse. What about more major procedures? To waive the requirement of consent whenever the facts may cause distress seems virtually to abandon it. If a particular patient with cancer of the prostate would be devastated by being told the facts, he could-be excluded from the trial. It seems unlikely that everyone will be excluded on these grounds. If too few of the remainder would consent when asked, can it be right to impose such a trial on uninformed and unconsenting patients? JONATHAN GLOVER Penicillin: There has been much speculation and debate about the 11 "silent" years between 1929, when Fleming's first published article announced his discovery of penicillin,' and 1940-1, when the Oxford workers firmly established it as a major chemotherapeutic agent.23 Why did Fleming not push on with the kind-of standard studies on animals then commonly used to assess antimicrobial agents? It was wrongly suggested -by Chain, for example4-that Fleming simply did not think of it. Apart from published evidence to the contrary,5,6
I clearly recall a visit which Fleming paid in 1932 to Professor John Cruickshank's bacteriology department in Aberdeen University. At that time I was the most junior member ofthat department, working on a scholarship. I was interested in a coccus which Professor Cruickshank had isolated and which inhibited growth of other bacteria. I showed it to Fleming, knowing of his publication on penicillin. Fleming showed polite interest but said it was not really anything very unusual; it had probably something to do with hydrogen peroxide production and was in any case not likely to be a good starting point for a beginner. "You'd need to work with a first rate biochemist," he said, and went on to explain why hM had not pursued penicillin. Apparently Raistrick, the foremost expert in the chemistry of moulds, had failed to extract and purify penicillin without losing its antibacterial activity; so Fleming had decided that the great potentialities of penicillin-of which he was quite certainly fully awarewould have to await the future and a new biochemical approach. This new approach, made possible by the brilliant insights of Chain along with Heatley and Abraham, led in 1940 and 1941 to the two famous Oxford papers which introduced the antibiotic era.2 3 There were hints from Fleming himself of the usefulness of penicillin-even impure and weak penicillin-in the treatment of local infections. These experiments are well described in Hare's excellent book on The Birth ofPenicillin7 and in his publication in Medical History.8 One of the most encouraging experiments described was the successful treatment in 1932 of pneumococcal conjunctivitis in Fleming's colleague Dr K B Rogers. Apart from Raistrick's lack of success in concentrating purified penicillin Fleming was influenced by the very rapid excretion of penicillin from the blood of injected animals along with the observation that it killed bacteria only slowly. This theoretical consideration happily did not deter Florey when he made the crucial experiment in 1940 which Fleming (and others also) could certainly have made at any time from 1930 onwards.
Wainwright and Swan have now published from Sheffield an extremely interesting paper which adds further evidence about early experiments with penicillin during the years between 1929 and 1940.9 Interestingly it was Florey who recalled that, at Sheffield, Dr Cecil George Paine, a young pathologist, had told him that he had successfully treated cases of conjunctivitis but had not published the results. Paine was a graduate of Fleming's hospital-St Mary's in London-and it was from Fleming that Paine secured a culture of the penicillin producing mould, but it was at the Royal Infirmary in Sheffield that he did his work on penicillin in 1930-1. The case notes ofthe late Mr A B Nutt, an assistant ophthalmic surgeon at Sheffield Royal Infirmary, and Paine's own records and recollections show that three patients with gonococcal neonatal ophthalmia, one with a staphylococcal eye infection, and one with a pneumococcal eye infection were treated successfully. The details now uncovered also clearly prove that Paine's work in Sheffield was done in late 1930 and early 1931-that is, before Florey's appointment as professor of pathology in 1932. The statement on page 219 of Macfarlane's book-to the effect that Paine's trials with penicillin were being made in 1932 in Florey's department at Sheffield6-is, therefore, erroneous; and so is another statement by Baldry to the same effect (page 106). 10 It was Florey himself who reminded Masters, author in 1946 of The Miracle Drug, of Paine's work," Florey knew of Paine's work because Paine told him about it. 12 Clearly it was others who linked Florey's Oxford work on penicillin with Paine's earlier work in Sheffield, which was done shortly before Florey took up his post in Sheffield. The misunderstanding was not surprising, but the detailed research now presented by Swan and Wainwright establishes that the account needs to be corrected in fairness to Paine.9
For his own part, Paine showed a creditably philosophical resignation to the real weight ofhis unpublished contribution -and how it might so easily have been so much greater and more accurately recorded in the histories of penicillin discovery. When Paine was asked by Wainwright at an interview where he placed himself in the penicillin story, he replied9: "Nowhere-a poor fool who didn't see the obvious when it 'was stuck in front of him."' In his modest remark Paine does himself less than justice. Paine's success with the ophthalmia infections was, indeed, the first clear and direct proof that penicillin had a useful place in clinical medicine,
